MiR-106b from hepatoma cells activates the AKT/ERK pathway via targeting GPM6A, resulting in upregulation of DYNC1I1 expression and ultimately promoting HCC cell proliferation [82]. Here, AKT1 is linked to hepatocellular carcinoma.